Psychedelics Investors wince as FDA panel rejects proposal to approve ‘molly’ for PTSD therapy Despite rejection from the advisory committee, the FDA won't make its final decision on the matter until August Rowan DunneJune 5, 2024
Psychedelics MAPS subsidiary raises over US$100M to support MDMA regulation The funding was led by the non-profit Helena, a diverse organization that aims to solve global problems Rowan DunneJanuary 5, 2024
News FDA lifts ban on study of therapists taking MDMA After two years of dispute, MAPS is celebrating the decision Natalia Buendia CalvilloMay 14, 2021